444119-00-0

Upstream product

• 69739-34-0 t-butyldimethylsiyl triflate 
• 444118-29-0 6-O-acetyl-2-azido-3-O-benzyl-4-tert-butyldimethylsilyl-2-deoxy-β-D-glucopyranoside 
• 108-48-5 2,6-dimethylpyridine 
• 138889-14-2 2-azido-3-O-benzyl-4,6-O-benzylidene-1-O-(tert-butyldimethylsilyl)-2-deoxy-β-D-glucopyranose 
• 138923-10-1 2-azido-4,6-O-benzylidene-2-deoxyl-1-O-tert-butyldimethylsilyl-β-D-glucopyranoside 
• 99049-65-7 tert-Butyldimethylsilyl-3,4,6-tri-O-acetyl-2-azido-2-desoxy-β-D-glucopyranosid 
• 171032-74-9 1,3,4,6-tetra-O-acetyl-2-azido-2-deoxy-D-glucopyranose 
• 120312-08-5 2-azido-3-O-benzyl-1-O-(tert-butyldimethylsilyl)-2-deoxy-β-D-glucopyranose 
• 99049-67-9 tert-Butyldimethylsilyl-2-azido-2-desoxy-β-D-glucopyranosid 

Relevant academic research and scientific papers

Tailored glycopolymers as anticoagulant heparin mimetics

Not to clot: Heparin and its low-molecular-weight derivatives are clinical therapeutics used to treat and prevent blood clots. The synthesis of heparin-based glycopolymers that are potent and potentially safer mimetics of heparin is described. The mimetic

Solid- and solution-phase synthesis of heparin and other glycosaminoglycans

Described is a modular, general synthetic strategy for the preparation in solution and on a solid support of heparin, heparin-like glycosaminoglycans, glycosaminoglycans and non-natural analogs of each of them. Additionally, the modular strategy provides

Modular synthesis of heparin oligosaccharides

A general, modular strategy for the first completely stereoselective synthesis of defined heparin oligosaccharides is described. Six monosaccharide building blocks (four differentially protected glucosamines, one glucuronic and one iduronic acid) were uti